Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomised, Double Blind, Placebo-controlled Study of Efficacy, Safety, and Tolerability of Kaprolac® K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp

NCT01137331 is registered in ClinicalTrials.gov with Moberg Pharma AB as lead sponsor.

NCT NCT01137331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01137331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomised, Double Blind, Placebo-controlled Study of Efficacy, Safety, and Tolerability of Kaprolac® K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp
Lead sponsor
Moberg Pharma AB
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2008
Completion date
April 30, 2008
Enrollment
201 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

seborrhoeic eczema of the scalp